Krystal Biotech, Inc.

NASDAQ (USD): Krystal Biotech, Inc. (KRYS)

Last Price

176.82

Today's Change

-0.96 (0.53%)

Day's Change

176.50 - 178.76

Trading Volume

108,723

Overview

Market Cap

5 Billion

Shares Outstanding

28 Million

Avg Volume

240,592

Avg Price (50 Days)

186.40

Avg Price (200 Days)

167.56

PE Ratio

44.88

EPS

3.94

Earnings Announcement

04-Nov-2024

Previous Close

177.78

Open

178.76

Day's Range

176.5 - 178.76

Year Range

93.95 - 219.34

Trading Volume

108,723

Price Change Highlight

1 Day Change

-0.54%

5 Day Change

2.01%

1 Month Change

-3.24%

3 Month Change

-11.96%

6 Month Change

7.84%

Ytd Change

41.50%

1 Year Change

56.57%

3 Year Change

253.08%

5 Year Change

390.21%

10 Year Change

1561.84%

Max Change

1561.84%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment